Abdominal Radiology

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Retrieved on: 
Montag, Mai 6, 2024
Congress, Society, Interventional radiology, Mayo Clinic, Urology, Safety, American Urological Association, Poster, American Roentgen Ray Society, TSX, Prostate cancer, Prostate, Salvage therapy, Abdominal Radiology, Patient, ARRS, AUA, ECR, Clinical trial, SIR, Annual general meeting, JUA, BPH, Turku University Hospital, EAU

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation (“TULSA”) procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (“BPH”) patients have been made at major medical meetings already in 2024.

Key Points: 
  • “The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease,” said Arun Menawat, Profound’s CEO and Chairman.
  • “The various presentations made at AUA and other major medical conferences have highlighted TULSA’s clinical use across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer,” added Dr. Menawat.
  • “Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the TACT FDA regulatory study.
  • We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of TULSA among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses.”

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Retrieved on: 
Dienstag, Juli 11, 2023
SAB, EASL, Radiation, Society, European Society of Radiology, ZEUS robotic surgical system, ESR, Diagnosis, Editorial board, Woman, Abdominal Radiology, CIRSE, ILCA, Gastrointestinal tract, Interventional radiology, MD, Circulatory system, Executive Committee, Cardiovascular and Interventional Radiological Society of Europe, Health, Medical imaging, Radiology, Liver

Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.

Key Points: 
  • Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.
  • Dr. Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
  • “It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” commented Eyal Morag, MD, Chief Medical Officer.
  • She serves as reviewer of several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals.

Chandana Lall, M.D., M.B.A., to join City of Hope as chair of diagnostic radiology and vice dean of clinical faculty affairs

Retrieved on: 
Freitag, April 28, 2023
Maimonides Medical Center, City of Hope National Medical Center, American College of Radiology, City of Hope, University, Society, Health, Medical imaging, Faculty of Management Studies – University of Delhi, Cancer, Business, Research, Abdominal Radiology, Radiology, Mount Sinai Beth Israel, Radiological Society of North America, Science, Lall, American Board of Commissioners for Foreign Missions, City, Magnetic resonance imaging, Boswell, Knowledge, American College, University of California, Irvine Medical Center, Recurrence, Hope

LOS ANGELES, April 28, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, has announced Chandana "Sandy" Lall, M.D., M.B.A., will join the organization as chair of Diagnostic Radiology and vice dean of clinical faculty affairs, effective July 1, 2023.

Key Points: 
  • LOS ANGELES, April 28, 2023 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States, has announced Chandana "Sandy" Lall, M.D., M.B.A., will join the organization as chair of Diagnostic Radiology and vice dean of clinical faculty affairs, effective July 1, 2023.
  • Lall currently serves as chair and professor of the radiology department at the University of Florida Jacksonville, and previously served as vice chair and professor of radiology and urology at the University of California Irvine.
  • "It is a great honor to join City of Hope's world-class diagnostic radiology department," said Lall.
  • "I look forward to partnering with my colleagues to integrate the most sophisticated imaging technologies into City of Hope's clinical trials and cancer therapies.